Podcast
MSL Talk: Tom Caravela
Compliance 101-Most common issues and MSL-related gray areas
Summary
In this episode, Jessica McLin and Melody Davis explore the intricacies of compliance and communication in medical affairs. Jessica shares her journey into entrepreneurship and discusses her work with Versant Learning Solutions. The conversation covers FDA standards, ethical collaboration with sales reps, and the importance of understanding company SOPs. They delve into strategies for navigating compliance gray areas and the role of training, especially in smaller companies. The episode also highlights the significance of professional development through conferences and the importance of leadership in enforcing compliance. Finally, they address key compliance rules and best practices for MSLs, including the Sunshine Act.
Today’s guests are Jessica McLin and Melody Davis of Versant Learning. We discuss MSL Compliance 101 and the most common issues and MSL-related gray areas.
In this episode we discuss:
- Jessica and Melody intro
- What Versant Learning does
- Compliance and what people need to know
- The most common gray areas to look out for
- Where can an MSL find compliance information outside their current organization
- The role of MSL Leadership in communicating compliance standards and how much of the effort lies on the MSL
- The most important for the MSLs to keep in mind
compliance in medical affairs, MSL compliance, FDA standards, ethical collaboration, professional development conferences
Related Topics
You May Also Like
MSL Talk: Tom Caravela
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO